Rezolve AI Slams Commerce.com's 'Poison Pill' Amid Hostile Takeover Bid
RZLV has more than doubled off its 52-week low of $1.1.
Summary
Rezolve AI plc strongly criticized Commerce.com, Inc.'s adoption of a "poison pill" defense, calling it a desperate attempt to entrench its board and prevent shareholders from considering Rezolve AI's acquisition offer.
Key Events · M&A and Partnerships · RZLV
-
Poison Pill Adopted
Commerce.com's Board of Directors adopted a stockholder rights plan, commonly known as a "poison pill," as a defensive measure against Rezolve AI's unsolicited acquisition offer.
-
Rezolve AI Condemns Action
Rezolve AI plc slammed the poison pill as a "desperate" attempt by Commerce.com's board to entrench itself and prevent shareholders from considering a value-maximizing offer.
-
Board Competence Questioned
Rezolve AI highlighted Commerce.com's 96% stock price decline from its post-IPO peak, questioning the board's competence ahead of the May 14 director election.
-
Investor Call Scheduled
Rezolve AI announced an investor call for April 15, 2026, at 0800 ET, to publicly present its strategic rationale for combining with Commerce.com.
Analysis · RZLV · Technology
This filing marks a significant escalation in the hostile takeover attempt by Rezolve AI for Commerce.com. The adoption of a poison pill by Commerce.com's board is a strong defensive maneuver designed to make an unsolicited acquisition more difficult and costly, potentially diluting any acquirer's stake. Rezolve AI's immediate and strong condemnation, coupled with its assessment of the plan's legality and fiduciary duty, indicates a continued aggressive pursuit of the acquisition. Shareholders of Commerce.com will likely face increased uncertainty and volatility as this battle unfolds, particularly with the upcoming director election on May 14, 2026, and Rezolve AI's scheduled investor call.
At the time of this filing, RZLV was trading at $2.60 on NASDAQ in the Technology sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.10 to $8.45. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.